新分子実体薬および新生物学的承認のためのFDA加速プログラムおよび開発タイムラインの使用 スポンサーの経験
Kanhai S Amin1, Bhav Jain2, Alissa Wong3
1Yale School of Medicine, New Haven, Connecticut, USA.
Clinical pharmacology and therapeutics
|September 5, 2025
まとめ
バイオ製薬会社は,新しい分子実体 (NME) と新しい生物学的薬のFDAの承認を得ています. 経験が不足しているにも関わらず 彼らはFDAのプロセスを 確立された企業と同じくらい効果的に 導いています
科学分野:
- 医薬品規制科学
- 薬の開発と承認プロセス
- バイオ医薬品産業の分析
背景:
- 小規模なバイオ製薬会社は より多くの新しい分子実体 (NME) を立ち上げています
- 新興企業は 将来の大ヒット薬の 発売を主導する見込みです
- 会社の経験は,FDAの迅速なプログラム使用とレビューのタイムラインに影響を与える可能性があります.
研究 の 目的:
- FDAの規制経路の違いを調べる 初めての薬のスポンサーと 経験のある薬のスポンサーの違いを調べる
- 2015年から2022年にかけてのNMEと新しい生物学的承認に対する企業の経験の影響を評価する.
主な方法:
- FDAのNMEと新しい生物学的承認 (2015-2022) の横断的な研究.
- スポンサーを"初代者"として分類するのは,初代者または最近の初代者の承認に基づいている.
- 公的なFDA情報源から,迅速なプログラム使用,承認時間,特許数に関するデータ抽出.
主要な成果:
- 355のNMEと新しい生物学的薬品が承認され,131 (36.9%) が初代企業によって承認された.
- 第一次承認の割合は 27.3% (2015年−2016年) から 43.7% (2021年−2022年) に大幅に増加した.
- プログラムの使用の迅速化,第1サイクル承認,PDUFAの期限達成,開発時間,または特許数では,初回企業と経験豊富な企業の間で大きな違いが見つかりませんでした.
結論:
- FDAの規制手続きを 経験豊富な企業と比べると 初めての製薬会社は成功しています
- 薬剤の承認を求める新規参入者には規制の経験不足が 障壁ではないようです
- 薬剤の革新と市場参入における新興バイオファーマの役割が 増えていることを支持しています
関連する概念動画
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Drug Regulation
1.8K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.8K
Preclinical Development: Overview
4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
Drug Discovery: Overview
8.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.7K
Drug Administration and Therapy Phases: Overview
737
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
737
Drug Nomenclature
2.2K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
2.2K


